Provepharm Life Solutions acquires Apollo

2 December 2020

France-based Provepharm Life Solutions today revealed it has acquired Apollo Pharmaceuticals USA, company that specializes in the commercialization of sterile injectable products for hospital use.

The business activities of Apollo Pharmaceuticals USA will be merged with those of the American subsidiary of the group, located in the Pennsylvania, USA. The financial terms of the deal will not be disclosed.

Provepharm's strategic purchase enables it to strengthen its position in the US market, particularly through the expansion of its product range, initially by integrating Apollo’s four registered products. This deal will also allow the group to streamline its commercial activity with hospitals and successfully launch its pipeline products.

Positioning Provepharm Life PublishSolutions closer to the end user will make it possible to better adapt its products and services to customers’ expectations.

The sales generated from the deal will allow the group to continue developing its portfolio, focused on hospital products in need of revitalization, through internal growth and external acquisitions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK